Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain by Pallarés Giner, Roman et al.
 Applications:Desktop Folder:2pall.oa
Mon Aug 21 0 14:09:23
 
474 THE NEW ENGLAND JOURNAL OF MEDICINE Aug. 24, 1995
 
RESISTANCE TO PENICILLIN AND CEPHALOSPORIN AND MORTALITY FROM SEVERE 
PNEUMOCOCCAL PNEUMONIA IN BARCELONA, SPAIN
 
R
 
OMAN
 
 P
 
ALLARES
 
, M.D., J
 
OSEFINA
 
 L
 
IÑARES
 
, M.D., M
 
IQUEL
 
 V
 
ADILLO
 
, M.D., C
 
ARMEN
 
 C
 
ABELLOS
 
, M.D., 
F
 
REDERIC
 
 M
 
ANRESA
 
, M.D., P
 
EDRO
 
 F. V
 
ILADRICH
 
, M.D., R
 
OGELIO
 
 M
 
ARTIN
 
, M.D., 
 
AND
 
 F
 
RANCESC
 
 G
 
UDIOL
 
, M.D.
 
Abstract
 
Background.
 
Penicillin-resistant strains of
 
Streptococcus pneumoniae 
 
are now found worldwide,
and strains with resistance to cephalosporin are being re-
ported. The appropriate antibiotic therapy for pneumo-
coccal pneumonia due to resistant strains remains contro-
versial.
 
Methods.
 
To examine the effect of resistance to pen-
icillin and cephalosporin on mortality, we conducted a 10-
year, prospective study in Barcelona of 504 adults with
culture-proved pneumococcal pneumonia.
 
Results.
 
Among the 504 patients, 145 (29 percent)
had penicillin-resistant strains of 
 
S. pneumoniae 
 
(minimal
inhibitory concentration [MIC] of penicillin G, 0.12 to 4.0
 
m
 
g per milliliter), and 31 patients (6 percent) had cepha-
losporin-resistant strains (MIC of ceftriaxone or cefotax-
ime, 1.0 to 4.0 
 
m
 
g per milliliter). Mortality was 38 percent
in patients with penicillin-resistant strains, as compared
with 24 percent in patients with penicillin-sensitive strains
(P
 

 
0.001). However, after the exclusion of patients with
polymicrobial pneumonia and adjustment for other pre-
dictors of mortality, the odds ratio for mortality in patients
with penicillin-resistant strains was 1.0 (95 percent con-
ﬁdence interval, 0.5 to 1.9; P
 

 
0.84). Among patients
treated with penicillin G or ampicillin, the mortality was
25 percent in the 24 with penicillin-resistant strains and
19 percent in the 126 with penicillin-sensitive strains
(P
 

 
0.51). Among patients treated with ceftriaxone or cef-
otaxime, the mortality was 22 percent in the 59 with pen-
icillin-resistant strains and 25 percent in the 127 with pen-
icillin-sensitive strains (P
 

 
0.64).
The frequency of resistance to cephalosporin increased
from 2 percent in 1984–1988 to 9 percent in 1989–1993
(P
 

 
0.002). Mortality was 26 percent in patients with
cephalosporin-resistant 
 
S. pneumoniae 
 
and 28 percent in
patients with susceptible organisms (P
 

 
0.89). Among
patients treated with ceftriaxone or cefotaxime, mortality
was 22 percent in the 18 with cephalosporin-resistant
strains and 24 percent in the 168 with cephalosporin-sen-
sitive organisms (P
 

 
0.64).
 
Conclusions.
 
Current levels of resistance to penicillin
and cephalosporin by 
 
S. pneumoniae 
 
are not associated
with increased mortality in patients with pneumococcal
pneumonia. Hence, these antibiotics remain the therapy of
choice for this disease. (N Engl J Med 1995;333:474-80.)
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S
 
INCE the ﬁrst descriptions two decades ago of
strains of 
 
Streptococcus pneumoniae
 
 with a decreased
susceptibility to penicillin (minimal inhibitory concen-
tration [MIC] of penicillin G, or the lowest concentra-
tion that inhibits pneumococcal growth, 
 

 
0.12 
 
m
 
g per
milliliter),
 
1,2
 
 there have been increasing reports of in-
fections caused by pneumococcal strains with high lev-
els of resistance to penicillin, to multiple antibiotics,
and more recently to cephalosporin.
 
3-13
 
 The prognostic
factors have been studied,
 
14,15
 
 but the effect of resist-
ance to penicillin and cephalosporin on mortality due
to pneumococcal pneumonia in adults is not known.
Despite the decreased susceptibility of pneumococci
to penicillin G, it is probable that penicillin, the time-
honored treatment for pneumococcal infection, should
remain the antibiotic of choice for some such infections.
However, it is not clear which types of pneumococcal
infection may be treated successfully with penicillin,
and up to what MIC.
On the basis of reports by us and others,
 
13,16
 
 pneu-
mococcal meningitis due to strains against which the
MIC of penicillin is 0.12 
 
m
 
g per milliliter or higher
should not be treated with that drug. Instead, either a
third-generation cephalosporin or vancomycin is rec-
ommended.
 
13,16
 
 Recently, cephalosporin therapy has been
reported to have failed in patients with pneumococcal
meningitis due to strains against which cefotaxime and
ceftriaxone have high MICs.
 
17
 
On the other hand, preliminary data suggest that in
some cases pneumococcal pneumonia against which
the MIC of penicillin is increased may respond to pen-
icillin or related 
 
b
 
-lactam antibiotics,
 
18-20
 
 because the
serum concentrations achieved with these drugs
 
21
 
 are
several times higher than the MICs. Nevertheless, the
efﬁcacy of penicillin is uncertain, and the role of ex-
tended-spectrum cephalosporins (ceftriaxone or cefo-
taxime) in treating resistant pneumococcal pneumonia
is not well deﬁned.
We sought to determine the factors inﬂuencing mor-
tality in adults with severe pneumococcal pneumonia,
as well as to assess the effect of resistance to penicillin
and cephalosporin on mortality in such patients. In ad-
dition, we evaluated the response to therapy with pen-
icillin or cephalosporin in relation to the degree of re-
sistance of the infecting strain.
 
M
 
ETHODS
 
Study Patients and Sources of Data
 
This 10-year, prospective study included patients with pneumonia
and no other focal disease, such as meningitis, for whom cultures of
blood, pleural ﬂuid, or specimens from the lower respiratory tract
were positive for 
 
S. pneumoniae. 
 
The study was carried out in the Hos-
pital de Bellvitge “Princeps d’Espanya,” a 1000-bed teaching institu-
tion in Barcelona, Spain, that serves an area with a population of
more than 1 million and admits only adult patients.
From January 1984 through December 1993, a total of 494 isolates
of 
 
S. pneumoniae
 
 were identiﬁed from blood samples in our microbi-
ology laboratory; 412 of these strains were isolated from patients with
pneumonia, whereas the remainder were from patients with menin-
gitis (49 patients) or bacteremia (33 patients). In addition, 138 pa-
tients whose blood cultures were negative had 
 
S. pneumoniae
 
 isolated
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from cultures of pleural ﬂuid (46 patients), cultures of specimens ob-
tained by transthoracic needle aspiration (37 patients), or cultures of
bronchoscopic specimens obtained by brushing that had more than
1000 colony-forming units (cfu) (55 patients). Thus, a total of 550 pa-
tients had diagnoses of culture-proved pneumococcal pneumonia. At
our institution, selected patients with severe pneumonia whose initial
diagnoses were unclear were included in a prospective protocol (ap-
proved by the ethics committee of the hospital) in recent years to
study the efﬁcacy of procedures to obtain bronchoscopic specimens
by brushing and transthoracic needle aspiration.
 
22
 
 Studies of suscep-
tibility to antibiotics were conducted for all the strains obtained; sev-
eral were included in previous reports.
 
18,23
 
When pneumococci were isolated from blood or another specimen,
the patient was evaluated by a staff member of the Infectious Disease
Service or the Pulmonary Disease Service. Most patients were seen
at outpatient clinics within one month after discharge. Data on mor-
tality were obtained by following the patients during hospitalization
and reviewing the clinical records of the outpatient clinic and records
of deaths.
We decided to include both patients with bacteremia and those
without bacteremia in the study, because no signiﬁcant differences in
mortality were found between the two groups (28 percent and 29 per-
cent, respectively). This study design allowed us to enroll more pa-
tients with strains resistant to penicillin and cephalosporin, so that
more accurate statistical comparisons could be made.
Among the 550 patients, 504 completed the study protocol; the re-
maining 46 were excluded from the univariate and multivariate anal-
yses. The mortality rate among these 46 patients was 26 percent, sim-
ilar to the rate of 28 percent among the patients who were included.
The entire group of 550 patients was included in the studies of sus-
ceptibility to antibiotics (Table 1).
 
Deﬁnitions
 
A diagnosis of pneumococcal pneumonia was made if a patient was
found to have infection of the lower respiratory tract in the clinical
history and on physical examination, as well as a pulmonary inﬁltrate
on chest radiography, and if 
 
S. pneumoniae
 
 was isolated from cultures
of one or more of the following types of specimens: blood, pleural ﬂu-
id, or specimens obtained by transthoracic needle aspiration or bron-
choscopic-specimen brushing. Patients who had only sputum cultures
positive for pneumococci were not included.
Mortality in the hospital was deﬁned to include deaths within one
month after the diagnosis of pneumonia. Serious underlying disease
was considered to be present if the patient had a conﬁrmed diagnosis
of one of the following: cancer, systemic vasculitis, or cirrhosis of the
liver; diabetes, if that disease had been diagnosed and the patient was
receiving hypoglycemic drugs; chronic renal failure, if the patient
was undergoing dialysis; human immunodeﬁciency virus (HIV) infec-
tion, if the patient had a positive enzyme-linked immunosorbent as-
say and Western blot assay for HIV type 1 or type 2; heart failure, if
the patient had a history of congestive heart failure, evidence of
heart failure, or both at the time of admission; and chronic pulmo-
nary disease, if the patient had had chronic respiratory symptoms for
more than three months during the preceding two years. Nosocomi-
ally acquired pneumonia was deﬁned by the presence of signs and
symptoms of lower respiratory tract infection that developed after
three days of hospitalization for an unrelated illness. Shock was de-
ﬁned as systolic blood pressure below 90 mm Hg together with hy-
poperfusion of the peripheral tissues. Multilobar involvement and
pleural effusion were considered to be present when more than one
pulmonary lobe was involved and when there was evidence of pleural
ﬂuid on a chest ﬁlm, respectively. Leukopenia was diagnosed if the
initial white-cell count was below 5000 per cubic millimeter. Polymi-
crobial pneumonia was considered to be present when 
 
S. pneumoniae
 
and another microorganism were isolated from cultures of blood or
specimens obtained from the lower respiratory tract; monomicrobial
pneumonia was considered to be present when
 
 S. pneumoniae
 
 was the
only microorganism isolated.
Antibiotic therapy was initially prescribed by the attending physi-
cian. When the results of the in vitro susceptibility testing were
known, the patient was evaluated by an infectious-disease specialist,
and most patients continued to receive the drugs initially prescribed,
because their conditions were clearly improving. For the analysis, pa-
tients were divided into three groups: the penicillin group (those
treated with penicillin G or ampicillin); the cephalosporin group
(those treated with ceftriaxone or cefotaxime); and the group treated
with other antibiotics. In order to include more patients with penicil-
lin-resistant disease in each group, those treated with penicillin G
and ampicillin were grouped together, as were those treated with cef-
triaxone and cefotaxime, because the drugs in each pair have almost
identical MICs and produce similar clinical responses. Antibiotic
therapy usually lasted from 7 to 14 days. The usual total intravenous
dose of penicillin G was 2 million U every 4 hours; of ampicillin, 2 g
every 6 hours; of ceftriaxone, 1 to 2 g every 24 hours; and of cefotax-
ime, 1 to 2 g every 6 hours. The other antibiotics were administered
according to standard criteria.
 
21
 
 
 
Microbiologic Studies
 
Strains of 
 
S. pneumoniae
 
 were identiﬁed by standard methods. All
strains were initially screened for susceptibility to antimicrobial
agents by the disk-diffusion method, with Mueller–Hinton blood agar
plates.
 
24
 
 A 1-
 
m
 
g oxacillin disk was used to detect all strains that had
decreased sensitivity to penicillin. The MICs of the oxacillin-resistant
strains were determined by the microdilution method in cation-sup-
plemented Mueller–Hinton broth with 5 percent whole deﬁbrinated
horse blood, at the appropriate concentration of antibiotic. The wells
of the microdilution plates were inoculated to a volume of 100 
 
m
 
l with
an inoculum containing 1 million cfu per milliliter. All pneumococcal
strains were stored frozen at 
 

 
40
 
°
 
C in skim milk until their MICs
were determined by the agar-dilution method. Two strains of 
 
S. pneu-
moniae
 
 were used as controls: American Type Culture Collection
(ATCC) 49619 (serotype 19) and ATCC 6303 (serotype 3). The MIC
was deﬁned as the lowest concentration of antibiotic that prevented
growth visible without the microscope after an overnight incubation
of plates at 35
 
°
 
C. The MICs of the antibiotics shown in Table 1 and
elsewhere in this article were determined by the agar-dilution meth-
od. Resistance to antimicrobial agents was deﬁned according to the
criteria of the National Committee for Clinical Laboratory Stand-
ards.
 
25
 
 Strains were serotyped at the Spanish Pneumococcal Refer-
ence Laboratory (Majadahonda, Madrid) with standard antiserum
 
*Of the 550 strains, 412 were isolated from blood cultures and 138 from cultures of speci-
mens from the lower respiratory tract. The most frequent serotypes of penicillin-resistant pneu-
mococci were serotypes 14 (in 19 percent of isolates), 6 (18 percent), 9 (17 percent), 23 (16
percent), 19 (15 percent), and 15 (7 percent); the most frequent serotypes of cephalosporin-
resistant pneumococci were serotypes 23 (in 28 percent of isolates), 6 (28 percent), 14 (23 per-
cent), 9 (10 percent), and 19 (5 percent). None of the strains were resistant to vancomycin at
a minimal inhibitory concentration (MIC) greater than 1.0 
 
m
 
g per milliliter.
†P values are for the comparison of the two periods for all MICs of each drug; they were
obtained by the chi-square test from two-by-k contingency tables, where k was the number of
categories of MICs studied.
 
Table 1. Susceptibility to Antibiotics in 550 Strains of Pneumo-
cocci Isolated from Patients with Pneumonia.
 
*
 
D
 
RUG
 
 
 
AND
 
 MIC (
 
m
 
g/ml) N
 
O
 
. (%) 
 
OF
 
 S
 
TRAINS
 
P V
 
ALUE
 
†
1984–1988 
(
 
N
 

 
221)
1989–1993 
(
 
N
 

 
329)
 
Penicillin G
 

 
0.06
0.12–1.0
2.0
4.0
178 (81)
29 (13)
11 (5)
3 (1)
214 (65)
67 (20)
35 (11)
13 (4)
 

 
0.001
Ceftriaxone or cefotaxime
 

 
0.5
1.0–4.0
216 (98)
5 (2)
299 (91)
30 (9)
 

 
0.002
Imipenem
 

 
0.12
0.25–1.0
208 (94)
13 (6)
271 (82)
58 (18)
 

 
0.001
Erythromycin
 

 
0.5
1.0–128.0
206 (93)
15 (7)
287 (87)
42 (13)
 

 
0.031
Tetracycline
 

 
2.0
4.0–128.0
124 (56)
97 (44)
219 (67)
110 (33)
 

 
0.021
Trimethoprim–sulfamethoxazole
 

 
0.05
1.0–2.0
 

 
4.0
110 (50)
20 (9)
91 (41)
173 (53)
33 (10)
123 (37)
 

 
0.661
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(Statens Serumsinstitut, Copenhagen, Den-
mark). A more detailed description of the mi-
crobiologic methods used is given else-
where.
 
18,23
 
 
 
Statistical Analysis
 
To study trends in pneumococcal pneumo-
nia and to avoid a selection bias, we included
only patients with bacteremic pneumonia in
the analysis, since blood cultures were per-
formed routinely, whereas the other diagnos-
tic methods were used selectively. We calcu-
lated the rates of infection acquired in the
hospital by subtracting three days from each
hospital stay and summing the residual dura-
tions of hospitalization.
The correlation of MICs for penicillin with
those for cephalosporin was determined by
the Pearson correlation coefﬁcient. The chi-
square test was used to compare the pro-
portions in samples with use of two-by-k con-
tingency tables, where k was the number of
categories of MICs studied.
The relation of covariates with mortality
was initially assessed by univariate analysis,
and odds ratios were then determined with a
logistic-regression model. An adjusted analy-
sis was performed with models constructed
by multiple logistic-regression analysis.
 
26
 
 In
this adjusted analysis, binary variables were
coded as 0 (absent) or 1 (present), and poly-
chotomous variables were coded with indica-
tor variables. All variables that were signiﬁ-
cant in any of the models were included.
Independent variables were checked for col-
linearity.
Age was subdivided into three groups: 19
to 39 years, 40 to 69 years, and 70 years or
older. The categories of cancer, cirrhosis, sys-
temic vasculitis, and disease necessitating
splenectomy were combined as serious under-
lying diseases, because they were all associat-
ed with increased mortality, as shown in
Table 2.
We considered the possibility that if drug-
resistant organisms are more virulent than
susceptible ones, then some variables related
to the severity of infection might be interme-
diate variables, rather than predisposing fac-
tors requiring statistical control. When we
compared the patients with penicillin-resist-
ant strains and those with susceptible strains,
however, there were no statistically signiﬁ-
cant differences in variables such as shock at
admission (18 percent and 14 percent, re-
spectively; P
 

 
0.13) and multilobar involve-
ment (26 percent and 29 percent, P
 

 
0.47),
suggesting that resistant strains were not
more virulent than susceptible strains, as has
been reported.
 
13,16
 
 
We included the entire cohort of 504 sub-
jects for whom data were complete in the
univariate and multivariate analyses (Tables 2
and 3). Other models that involved only pa-
tients with monomicrobial pneumonia (those in
which 
 
S. pneumoniae
 
 was the only microorgan-
ism isolated from cultures) and included the
same covariates are also shown (Table 3). To
measure the effect of drug resistance on mor-
tality while adjusting for other terms, we ﬁtted
the variable of resistance to penicillin into the
models, whether it was signiﬁcant or not. 
In assessing responses to antibiotic thera-
 
*Pneumococcal pneumonia was diagnosed on the basis of blood cultures in 407 patients and cultures of specimens from
the lower respiratory tract in 97. CI denotes conﬁdence interval, and HIV human immunodeﬁciency virus.
†Serious underlying disease was considered to be present when the patient had one or more of the following: cancer (39
deaths among 91 patients), liver cirrhosis (23 deaths among 40 patients), systemic vasculitis (1 death among 8 patients), or
splenectomy (2 deaths among 2 patients).
‡In addition to 
 
S. pneumoniae, 
 
other microorganisms isolated in the patients with polymicrobial pneumonia were 
 
Hae-
mophilus inﬂuenzae 
 
(in 14 patients), 
 
Staphylococcus aureus 
 
(12), 
 
Salmonella enteritidis 
 
(2), 
 
Pseudomonas aeruginosa 
 
(4),
 
Escherichia coli 
 
(4), acinetobacter species (4), klebsiella species (1), and enterobacter species (1).
§Resistance to penicillin G was deﬁned by an MIC of penicillin G 
 

 
0.12 
 
m
 
g per milliliter. The distribution of deaths
according to the MIC of penicillin G was as follows: 0.12 
 
m
 
g per milliliter, 5 deaths among 14 patients; 0.25 
 
m
 
g per milliliter,
10 deaths among 22 patients; 0.5 
 
m
 
g per milliliter, 6 deaths among 15 patients; 1.0 
 
m
 
g per milliliter, 14 deaths among 38
patients; 2.0 
 
m
 
g per milliliter, 16 deaths among 43 patients; and 4.0 
 
m
 
g per milliliter, 4 deaths among 13 patients.
¶Resistance to cephalosporin was deﬁned by an MIC of ceftriaxone or cefotaxime 
 

 
1.0 
 
m
 
g per milliliter. The distribution
of deaths according to the MIC of ceftriaxone or cefotaxime was as follows: 1.0 
 
m
 
g per milliliter, 5 deaths among 25 patients;
2.0 
 
m
 
g per milliliter, 3 deaths among 5 patients; and 4.0 
 
m
 
g per milliliter, 1 patient, who survived.
 

 
Antibiotic therapy was given as follows: penicillin G to 115 patients, ampicillin to 37, ceftriaxone to 161, cefotaxime to
38, erythromycin to 34, erythromycin plus cephalosporin to 26, clindamycin to 9, vancomycin to 5, imipenem to 9, and other
antimicrobial agents to 60.
**These patients died before antibiotic therapy was started.
 
Table 2. Univariate Analysis of Factors Inﬂuencing Mortality in 504 Adult Patients with
Pneumococcal Pneumonia.
 
*
 
F
 
ACTOR
 
M
 
ORTALITY
 
U
 
NADJUSTED
 
 O
 
DDS
 
 R
 
ATIO
 
(95% CI) P V
 
ALUE
NO
 
. 
 
OF
 
 
 
DEATHS
 
/
 
NO
 
. 
 
OF
 
 
 
PATIENTS PERCENT
 
Demographics and history
 
Age (yr)
19–39
40–69
 

 
70
19/114
71/252
50/138
17
28
36
1.0 (1.1–1.1)
1.9 (1.1–3.4)
2.8 (1.5–5.1)
—
 

 
0.021
 

 
0.001
Sex
Male
Female
100/376
40/128
27
31
1.0 (1.1–1.1)
1.2 (0.8–1.9)
—
 

 
0.311
Serious underlying disease†
No
Yes
80/370
60/134
22
45
1.0 (1.1–1.1)
2.9 (1.9–4.4)
—
 

 
0.001
Diabetes
No
Yes
124/449
16/55
28
29
1.0 (1.1–1.1)
1.0 (0.8–3.8)
—
 

 
0.821
Chronic renal failure
No
Yes
135/488
5/16
28
31
1.0 (1.1–1.1)
1.1 (0.4–3.4)
—
 

 
0.751
HIV infection
No
Yes
134/462
6/42
29
14
1.0 (1.1–1.1)
0.4 (0.1–0.9)
—
 

 
0.051
Heart failure
No
Yes
117/453
23/51
26
45
1.0 (1.1–1.1)
2.3 (1.3–4.2)
—
 

 
0.004
Chronic pulmonary disease
No
Yes
109/385
31/119
28
26
1.0 (1.1–1.1)
0.8 (0.5–1.4)
—
0.631
Findings at presentation
Shock
No
Yes
85/429
55/75
20
73
1.0 (1.1–1.1)
11.1 (6.3–19.5)
—
0.001
Multilobar involvement
No
Yes
67/364
73/140
18
52
1.0 (1.1–1.1)
4.8 (3.1–7.3)
—
0.001
Leukopenia (5000 cells/mm3)
No
Yes
98/436
42/68
22
62
1.0 (1.1–1.1)
5.5 (3.2–9.5)
—
0.001
Polymicrobial pneumonia‡
No
Yes
115/464
25/40
25
62
1.0 (1.1–1.1)
5.0 (2.5–9.9)
—
0.001
Place pneumonia acquired
Community
Hospital
91/396
49/108
23
45
1.0 (1.1–1.1)
2.7 (1.7–4.3)
—
0.001
Penicillin resistance§
No
Yes
85/359
55/145
24
38
1.0 (1.1–1.1)
1.9 (1.3–2.9)
—
0.001
Cephalosporin resistance¶
No
Yes
132/473
8/31
28
26
1.0 (1.1–1.1)
0.9 (0.4–2.1)
—
0.891
Antibiotic therapy
Penicillin G or ampicillin 31/152 20 1.0 (1.1–1.1) —
Ceftriaxone or cefotaxime 52/199 26 1.3 (0.8–2.2) 0.211
Other 47/143 33 1.9 (1.1–3.2) 0.021
None** 10/10 — — —
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py, we studied only patients with monomicrobial pneumococcal pneu-
monia, comparing the mortality of patients with resistant strains with
that of patients with susceptible strains with regard to each antimi-
crobial agent (or group of agents) (Table 4). Because the study was
not a randomized clinical trial, comparisons between groups of anti-
biotics were avoided. P values of less than 0.05 were considered to
indicate statistical signiﬁcance, and all reported P values are two-
tailed.
RESULTS
Of the 504 adults with severe pneumococcal pneu-
monia, 145 (29 percent) had penicillin-resistant strains
and 31 (6 percent) had cephalosporin-resistant strains.
During the study period, we observed a signiﬁcant in-
crease in resistance to penicillin, cephalosporin, imi-
penem, and erythromycin (Table 1). The distribution of
serotypes is shown in the ﬁrst footnote to Table 1.
Trends in Bacteremic Pneumococcal Pneumonia
The incidence of community-acquired bacteremic
pneumococcal pneumonia increased during the study
period (Fig. 1). This increase was due mainly to the
inclusion of the patients with HIV (who accounted for
4 episodes of pneumonia in 1984–1988 and 34 episodes
in 1989–1993). The incidence of bacteremic pneumo-
coccal pneumonia acquired in the hospital did not in-
crease signiﬁcantly (in 1984–1988 there were 0.019
and in 1989–1993 0.030 episodes per 1000 patient-
days).
Analysis of Mortality
Overall mortality was 28 percent (140 of 504), and
most deaths occurred within seven days after diagno-
sis (Fig. 2). The factors inﬂuencing mortality in the
univariate analysis are shown in Table 2. Patients with
HIV had lower mortality than those without HIV, but
after we controlled for age (the pa-
tients with HIV being younger than
those without HIV) the risk of death
did not differ signiﬁcantly (adjusted
odds ratio for the patients with HIV,
0.7; 95 percent conﬁdence interval,
0.2 to 1.9; P0.51).
In the multivariate analysis, the
independent prognostic factors for
mortality were age of 70 years or
above, serious underlying disease,
heart failure, shock, multilobar in-
volvement, leukopenia (5000 cells
per cubic millimeter), nosocomially
acquired pneumonia, and polymicro-
bial pneumonia (Table 3). The types
of microorganisms recovered in the
patients with polymicrobial pneumo-
nia are shown in the third footnote to
Table 2.
Overall, the mortality rate among
the patients with penicillin-resistant
strains was 38 percent, and among
those with susceptible strains it was
24 percent (P0.001) (Table 2), but
after we controlled for other predictors of mortality
the odds ratios for those with resistant strains were 1.3
(95 percent conﬁdence interval, 0.7 to 2.2; P0.32) in
the entire cohort and 1.0 (95 percent conﬁdence in-
terval, 0.5 to 1.9; P0.84) among the patients with
monomicrobial pneumococcal pneumonia. Similar re-
sults were obtained for the patients with bacteremia
(Table 3).
When conditions that resulted from the infection,
such as shock at the time of admission and multilobar
involvement, were not included in the model for the en-
*Patients with monomicrobial pneumonia were those in whom S. pneumoniae was the only microorganism isolated from
blood cultures or cultures of specimens from the lower respiratory tract. OR denotes odds ratio, and CI conﬁdence interval.
†Deﬁned as an MIC of penicillin G 0.12 mg per milliliter.
‡Serious underlying disease was considered to be present when the patient had one or more of the following: cancer, liver
cirrhosis, systemic vasculitis, and splenectomy.
Table 3. Multivariate Analysis of Factors Inﬂuencing Mortality in the Entire Cohort of
504 Patients with Pneumococcal Pneumonia and among All Patients with Monomi-
crobial Pneumonia and Only Those with Bacteremia.*
VARIABLE
ENTIRE COHORT 
(N  504) PATIENTS WITH MONOMICROBIAL PNEUMONIA
ALL (N  464)
WITH BACTEREMIA 
(N  392)
Adjusted OR
(95% CI)
P
Value
Adjusted OR
(95% CI)
P
Value
Adjusted OR
(95% CI)
P
Value
Penicillin resistance† 1.3 (0.7–2.2)1 0.321 1.0 (0.5–1.9)1 0.841 0.9 (0.4–1.9) 0.841
Age (yr)
19–39
40–69
70
1.0 (1.1–1.1)1
1.0 (0.9–4.1)1
2.4 (1.2–5.2)1
0.851
0.031
1.0 (1.1–1.11)
1.2 (0.5–2.7)1
2.7 (1.2–6.5)1
0.641
0.021
1.0 (1.1–1.1)
0.9 (0.3–2.3)
2.4 (0.9–6.3)
0.861
0.061
Serious underlying disease‡ 1.9 (1.2–3.5)1 0.021 1.8 (1.1–3.4)1 0.051 2.2 (1.1–4.5) 0.021
Heart failure 2.0 (1.1–4.4)1 0.051 2.2 (1.1–4.8)1 0.041 1.8 (0.7–4.6) 0.171
Shock 7.5 (3.8–14.6) 0.001 9.0 (4.4–18.3) 0.001 13.4 (5.9–30.3) 0.001
Multilobar involvement 4.4 (2.6–7.5)1 0.001 3.8 (2.2–6.7)1 0.001 3.7 (2.0–7.0) 0.001
Leukopenia (5000
cells/mm3)
3.3 (1.6–6.9)1 0.001 3.2 (1.5–6.9)1 0.002 3.0 (1.2–7.0) 0.011
Nosocomial pneumonia 2.0 (1.1–3.8)1 0.021 2.9 (1.5–5.7)1 0.001 4.6 (2.0–10.7) 0.001
Polymicrobial pneumonia 5.6 (2.3–13.6) 0.001 — — — —
*The 48 patients who had polymicrobial pneumonia or who did not receive antibiotic ther-
apy (or both) were excluded from this analysis. Eleven patients infected with penicillin-resist-
ant strains and included here were also included in a previous report.18
†The other antibiotics administered included erythromycin, erythromycin plus cephalospor-
in, clindamycin, vancomycin, and imipenem.
Table 4. Mortality among 456 Patients with Monomicrobial Pneu-
mococcal Pneumonia, According to Type of Antibiotic Therapy
and Degree of Resistance of the Infecting Strain.*
ANTIBIOTIC AND RESPONSE OF STRAIN ANTIBIOTIC ADMINISTERED
PENICILLIN G
OR AMPICILLIN
CEFTRIAXONE
OR CEFOTAXIME OTHER†
no. of patients who died/no. in group (%)
Penicillin G
Susceptible (MIC, 0.06 mg/ml) 24/126 (19) 32/127 (25) 18/871 (21)
Resistant (MIC, in mg/ml)
0.12 to 1.0
2.0
4.0
All
4/14  (11)
1/9  (11)
1/1  (11)
6/24  (25)
5/33  (11)
7/18  (11)
1/8  (11)
13/59  (22)
11/22  (11)
2/8  (11)
1/3  (11)
14/33  (42)
Ceftriaxone or cefotaxime
Susceptible (MIC, 0.5 mg/ml) 41/168 (24) 29/145 (20) 30/114 (26)
Resistant (MIC, in mg/ml)
1.0
2.0
4.0
All
3/16  (11)
1/2  (11)
—
4/18  (22)
1/4  (11)
—
0/1  (11)
1/5  (20)
1/5  (11)
1/1  (11)
—
2/6  (33)
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tire cohort, and after we adjusted that analysis for the
other terms shown in Table 3, resistance to penicillin
was still not signiﬁcantly associated with mortality
(adjusted odds ratio, 1.1; 95 percent conﬁdence inter-
val, 0.6 to 1.8; P0.62). Similar results were obtained
when the same covariates were studied in the model
for the patients with monomicrobial pneumonia (data
not shown).
Response to Antibiotic Therapy
As Table 4 shows, among the patients with monomi-
crobial pneumococcal pneumonia who were treated
with penicillin G or ampicillin, the mortality rates
among the 24 patients with penicillin-resistant strains
and the 126 patients with susceptible strains were 25
percent and 19 percent, respectively (odds ratio, 1.4; 95
percent conﬁdence interval, 0.5 to 3.9; P0.51). After
adjustment, the odds ratio was 0.9 (95 percent conﬁ-
dence interval, 0.3 to 2.8; P0.90). It is important to
note that eight of the nine patients with MICs of 2 mg
per milliliter recovered and that the only patient with
an MIC of 4 mg per milliliter (a patient with severe un-
derlying disease) died.
Among the patients treated with ceftriaxone or cefo-
taxime, the mortality rates among the 59 patients with
penicillin-resistant strains and the 127 patients with
susceptible strains were 22 percent and 25 percent, re-
spectively (odds ratio, 0.8; 95 percent conﬁdence inter-
val, 0.4 to 1.7; P0.64). After adjustment, the odds ra-
tio was 0.4 (95 percent conﬁdence interval, 0.2 to 1.1;
P0.10).
Among the patients treated with other antibiotics,
the mortality rates among the 33 with penicillin-resist-
ant strains and the 87 with susceptible strains were 42
percent and 21 percent, respectively (odds ratio, 2.8; 95
percent conﬁdence interval, 1.2 to 6.6; P0.02), but
this difference was not signiﬁcant after adjustment (ad-
justed odds ratio, 1.4; 95 percent conﬁdence interval,
0.4 to 4.1; P0.54).
Emergence of Resistance to Cephalosporins
Strains with decreased susceptibility to cephalospor-
in (MIC of ceftriaxone or cefotaxime, 1.0 mg per mil-
liliter) were found in 2 percent of patients in 1984–
1988 and in 9 percent in 1989–1993 (P0.002) (Table
1). There was a close correlation between the MICs of
the cephalosporins and that of penicillin (r0.85,
P0.001).
During the ﬁrst years of the study, the MICs of cef-
triaxone and cefotaxime were usually two to four times
smaller than that of penicillin G, but in the more recent
years they were usually one to two times smaller. More-
over, we observed ﬁve instances of resistance in which
the MICs of the cephalosporins were equal to that of
penicillin G, and one instance in which the MIC of cef-
triaxone or cefotaxime was 4 mg per milliliter and that
of penicillin G was 0.5 mg per milliliter (the patient re-
covered with penicillin therapy).
Overall, the mortality rate among the patients with
cephalosporin-resistant pneumococcal strains was sim-
ilar to that among the patients with cephalosporin-sus-
ceptible strains (26 percent vs. 28 percent; odds ratio,
0.9; 95 percent conﬁdence interval, 0.4 to 2.1; P0.89)
(Table 2). Among the patients treated with ceftriaxone
or cefotaxime, the mortality rates among the 18 with
cephalosporin-resistant strains and the 168 with sus-
ceptible strains were 22 percent and 24 percent, re-
spectively (odds ratio, 0.8; 95 percent conﬁdence inter-
val, 0.4 to 1.7; P0.64) (Table 4).
DISCUSSION
Over the past two decades, pneumococci have be-
come increasingly resistant to penicillin and other an-
tibiotics.8-10,27,28 The more recent identiﬁcation of ceph-
alosporin-resistant strains is a cause for additional
concern.13,29 At our institution, we have seen an increase
in the frequency of infections due to pneumococci re-
sistant to penicillin, cephalosporin, and erythromycin,
the antibiotics used most commonly to treat pneumonia
(Table 1).
During the study period, we found an increasing
trend toward community-acquired bacteremic pneumo-
coccal pneumonia (Fig. 1). This was at least partly due
to the greater numbers of HIV-infected patients, who
are at higher risk for pneumococcal infections.30,31 The
incidence of bacteremic pneumococcal pneumonia ac-
quired in the hospital did not increase signiﬁcantly. Al-
Figure 1. Trends in Community-Acquired Bacteremic
Pneumococcal Pneumonia.
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though outbreaks of pneumococcal pneumonia have
been reported in hospitals and prisons,18,32 no outbreaks
were detected in the present study.
The overall mortality reported in patients with pneu-
mococcal bacteremia (and usually with pneumonia)
has remained unchanged at about 25 percent over the
past four decades14,15,33-37 and is close to the 28 percent
mortality in our study. The factors associated with in-
creased mortality in this study (Table 3) are clinically
consistent and similar to those reported previously.14,15
The increased mortality from nosocomially acquired
infection38 probably reﬂects the greater severity of un-
derlying disease in these patients. There was also high-
er mortality among our patients with polymicrobial
pneumonia, who had other serious pathogens in ad-
dition to pneumococci. On the other hand, the HIV-
infected patients had lower mortality, probably because
of their relative youth. In other reports HIV infection
was not found to affect mortality from pneumococcal
pneumonia signiﬁcantly.30,31 
In our study, the patients with penicillin-resistant
pneumococcal strains had higher mortality than those
with penicillin-susceptible strains in the univariate
analysis. However, after adjustment for other variables,
resistance to penicillin was not associated with in-
creased mortality. The patients with penicillin-resistant
strains had more serious underlying conditions than
the patients with penicillin-susceptible strains.18 Simi-
larly, the case fatality rate of South African children
with penicillin-resistant pneumococcal infections did
not differ signiﬁcantly from that of children with peni-
cillin-susceptible infections.6 In our study, resistance to
cephalosporin was also not associated with increased
mortality.
Our study was not designed to compare the efﬁcacy
of various antibiotics, and it was not a randomized clin-
ical trial. Therefore, the response to antibiotic therapy
was analyzed by comparing mortality in patients with
resistant strains and patients with susceptible strains
with regard to each antimicrobial agent (or group of
agents) (Table 4).
Our data suggest that high-dose intravenous penicil-
lin G (150,000 to 200,000 U per kilogram of body
weight per day) may be effective in patients with pneu-
mococcal pneumonia due to strains for which the MIC
of penicillin ranges from 0.12 to 2 mg per milliliter. Cef-
triaxone or cefotaxime may be a good alternative when
the MIC of penicillin is higher and those of ceftriaxone
and cefotaxime are 2 mg per milliliter or less. It is not
known whether pneumonia due to strains for which the
MIC of penicillin was 4 mg per milliliter or higher
would respond to penicillin therapy, or whether infec-
tions for which the MICs of ceftriaxone and cefotaxime
were 4 mg per milliliter or higher would respond to
cephalosporin therapy.
Careful selection of an effective antibiotic for the ini-
tial empirical therapy requires an awareness of pat-
terns of susceptibility in the patient’s geographic area.
We think that identifying patients at greater risk of dy-
ing (Table 3) or of having a resistant strain18,39 may
help in choosing the appropriate therapy. For example,
patients with a low probability of death and no risk fac-
tors for penicillin-resistant strains could be given initial
empirical treatment with high-dose intravenous peni-
cillin G, ampicillin, or amoxicillin. In patients with a
higher risk of death or with risk factors for pneumococ-
ci with a high level of resistance to penicillin, it would
be prudent to start empirical treatment with an alter-
native antibiotic. In these cases, ceftriaxone or cefotax-
ime may be given, together with erythromycin when the
presence of legionella or another atypical pathogen can-
not reasonably be ruled out. Other alternatives, such as
imipenem or vancomycin, ought to be considered in re-
gions where a high level of resistance to cephalosporins
has become prevalent.
In summary, our study suggests that the current lev-
els of resistance to penicillin and cephalosporin do not
appear to increase mortality in patients with pneumo-
coccal pneumonia. High-dose intravenous penicillin may
be effective for infections in which the MIC of penicillin
is up to 2 mg per milliliter, and ceftriaxone or cefotax-
ime may be effective when the MIC of penicillin is
higher. However, the emergence of high levels of resist-
ance to cephalosporin is an alarming problem. It is to
be hoped that administering the existing pneumococ-
cal vaccine to adults at an earlier age as well as devel-
oping a new vaccine suitable for children will help to
prevent these difﬁcult-to-treat infections in the future.40 
We are indebted to the members of the medical staffs of the Infec-
tious Disease, Respiratory Disease, and Internal Medicine services,
who provided care to many of the patients included in this study, and
to the staff members of the Microbiology Service who performed the
studies of susceptibility to antibiotics.
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